Assignment #2 Dissemination Plan
docx
keyboard_arrow_up
School
San Francisco State University *
*We aren’t endorsed by this school
Course
BRH606
Subject
Health Science
Date
Nov 24, 2024
Type
docx
Pages
6
Uploaded by HighnessBoulder7628
Assignment #2 Dissemination Plan
Student Name:
Student Id:
Introduction
COVID-19 infected 274 million people as of December 20, 2021, and 5.35 million died as a
result. SARS-CoV-2, which is an extremely contagious form of the virus, continues to pose a
health concern to the general public, both physically and mentally. This has resulted in an
increase in health disparities.
By providing the COVID-19 vaccine, there will be a significant
reduction in the spread of the pandemic and the number of associated deaths
Research Findings and Product In an analysis published in the Journal of The New England Medical Association (NEJM),
bivalent vaccines were found to be 58.7% more effective than monovalent vaccines at
reducing hospitalizations[CITATION Car1 \l 1033 ]. Bivalent vaccines also prevented infection
61.8% more effectively than monovalent vaccines. When SARS-CoV-2 is boosted with a
bivalent vaccine, CoVID-19 is more susceptible to severe infection[ CITATION NIH23 \l 1033 ].
This plan wants to disseminate information about the effectiveness of new covid 19 bivalent
vaccine to public so that they can be encouraged too get shots of bivalent vaccine and cases
of covid 19 can be controlled. There are various problems which are faced by healthcare
staff as people do not trust covid vaccines and denying for vaccination in some area. The
findings of this research will improve the patient safety by showing them successful impact
of covid 19 bivalent vaccine and motivate them to get vaccination. It is an innovative way to
tackle the current problem where people are not ready to take vaccines. The results of this
study will help healthcare practitioners to support their arguments with valid results and
encourage population for vaccination.
Identifying End Users The end users of this selected product will be Nurses, genera population, family physicians,
health care administrations, and doctors. This product will be useful for end users as it will
increase the vaccination rate by motivating the general population to get the shots of covid
bivalent vaccine. Moreover, this product will also be helpful for nurses and doctors as it will
increase their efficiency and improve patient care by reducing the number of covid cases.
However, the recent negative thoughts and perception of general population towards
previous vaccines can hinder their interest in this new product. Apart from this end users are
will be involved in this product when healthcare workers start giving doses of bivalent
vaccine and they evaluate the impact of bivalent vaccine. The negative perception of general
public can be barrier in using this product to overcome this barrier people are suggestion to
consults with their healthcare professionals regarding covid bivalent vaccine and they will
provide information with its success rate. As well as promoting positive health behaviours
and strengthening acceptance of scientific claims, this product may be able to promote
prosocial behaviour and healthy living. It is therefore crucial to increase empirical efforts to
strengthen national identification as well as identification with all of humanity at large.
Dissemination Partners
The partners who will help to disseminate this information will be healthcare workers, nurse,
physicians. They will interact with end users to inform them about the success rate of
bivalent covid vaccine. To provide broad protection against COVID-19 caused by the omicron
strain, the bivalent COVID-19 vaccines contain a component from the original COVID-19
vaccine and a component from the omicron variant vaccine. Moreover, other partners like
organizations such as institute of healthcare improvements and local hospitals will also help
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
as disseminate partners. They will importantly partners as they have professional experience
and credibility, and expert in improving quality. The product will fit with goal of these parties
as their common goal is to ensure patient safety and reduce the number of covid19 cases. So
it will attract the these partners to work with me and promote the vaccination. Regular
meetings will be conducted with dissemination partners so that they can include this
product on their communication channels. Communicating the Message To communicate the information related to new covid-19 bivalent vaccine different media
channels will be used. The combination of different media will be selected to disseminate
the information to end users. TV and radio interviews are considered as the effective
method as it will reach large number of end users. Moreover, clinical speciality associations
will also be encouraged to disseminate information along with regular newspaper news and
showing interviews of Health experts on new covid-19 bivalent vaccine. Realistically, presses
releases, TV and radio channels will be used to disseminate information related to the
product. As these methods have large reach so they will help to aware the use and benefits
of product to end users. Difficulties such as lack of trust can be arise but they will be
overcome by showing expert interviews time to time t gain end users trust. Evaluating Success Success of dissemination plan will be measured through different ways. The first success
criteria for the dissemination plan will be percentage of vaccination taken by people. The
increased percentage wills how that product information is positively disseminated to the
end users. Moreover, number of inquiries received and number of vaccine doses
manufactured will be the measured key indicators of the success of dissemination plan.
Apart from this to evaluate the success of the dissemination plan feedback will also be
obtained from end users regarding impact of covid-19 bivalent vaccine on their body and
immunity. All the dissemination partners will also be involved in evaluation of success of
plan at their level so that they can gather data like number of vaccination done and attitude
of end user towards covid 19 bivalent vaccine. Summary of Dissemination Plan
My product for this dissemination plan is new Covid-19 bivalent vaccine. It can used to
enhance immunity of population and reduce the chances of covid infection. As compare to
previous monovalent vaccinations this new bivalent product is more strong and efficient. My
primary end users are local population with whom information related to this dissemination
plan will be shared. I also plan to involve users in dissemination efforts by encouraging them
to take vaccinations. Furthermore, I use individuals such as nurses, doctors, pharmacists and
organizations like institute for health improvement. The ways through which I will
communicate the results TV, radio and press releases. These medias will help me to deliver
the message across the audience. The potential obstacles that I face in disseminating
negative perception of people about previous vaccination. To evaluate the dissemination
plan indicators like number of end users who take bivalent vaccination. The measurable
indicators like number inquiries received related to vaccine and manufactured units of
vaccine. Moreover, I plan to encourage feedback from end users and disseminate partners to
improve the product in future.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help